Developer docs
API playgroundTry for free, no card

Search company profiles

NeuImmune

Full company profile

uuid0004jf3

Namestring
NeuImmune
Legal namestring
NeuImmune, Inc.
Websiteurl
neuimmune.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

NeuImmune, Inc. is an early-stage biotechnology company developing precision glycoengineered biologics for orphan diseases and infectious disease applications. The company was founded in 2020 by scientists from the University of Maryland, University of California San Diego, and the Technical University of Denmark, and is headquartered in Sykesville, Maryland with 11-50 employees. Its core technology consists of two proprietary platforms: the geCHO BioDesign Platform, a comprehensive panel of glycoengineered Chinese Hamster Ovary (CHO) cells capable of uniformly producing diverse human-like glycoforms of therapeutic proteins and vaccine antigens, combined with AI tools for optimal glycoform identification and bioproduction optimization; and ICAM-1 Targeting Technology, which fuses geCHO proteins with ICAM-1-binding peptides to enable enhanced cellular delivery and enzymatic activity, including CNS and visceral organ access via intravenous dosing for lysosomal storage disorders. The company licenses the geCHO platform from a program developed with over $50M in support from the Novo Nordisk Foundation at the Technical University of Denmark.

NeuImmune operates a platform-plus-pipeline business model, applying its dual technology stack to advance preclinical pipeline programs including ICAM-1-ASM for Niemann-Pick Disease Types A and A/B (addressing neurological involvement not covered by existing enzyme replacement therapy Olipudase alfa) and recombinant Antithrombin (rhAT) for antithrombin deficiency. The company is pre-commercial with no disclosed product revenue; it monetizes through research grants, strategic government contracts (notably a $22.2M BARDA BioMaP-Consortium award for filovirus antibody biomanufacturing in partnership with Ginkgo Bioworks, announced November 2025), and a strategic licensing/government-funded collaboration model. Its customer segments are vertical-organized: primary focus on orphan disease patients with lysosomal storage disorders (particularly Niemann-Pick disease), and a secondary infectious disease segment targeting filoviral hemorrhagic fevers including Ebola and Sudan Virus. Pricing is not publicly disclosed as the company remains in preclinical development.

The company is led by Executive Chairman Thomas Fuerst, PhD (former Scientific Founder at MedImmune, Director of Biodefense at BARDA, and Director at DARPA), CTO Nathan Lewis, PhD (CHO genome sequencing pioneer and systems biology/AI expert), VP of gCHO Cell Manufacturing Bjorn Voldborg, MSc (former head of the NNF-funded National Biologics Facility at DTU), and Board Advisor Armand Girard, MBA (former CBO at GlycoMimetics and VP at Shire Pharmaceuticals). NeuImmune relies on scientific publications, press releases, and institutional partnerships (NIH, BARDA, Novo Nordisk Foundation, Ginkgo Bioworks, Kemp Proteins) for visibility and demand generation rather than commercial sales infrastructure.

Short descriptiontext

NeuImmune is an early-stage biotechnology company developing precision glycoengineered biologics using its proprietary geCHO BioDesign platform and ICAM-1 targeting technology, advancing preclinical pipeline programs for orphan diseases including Niemann-Pick disease and antithrombin deficiency.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSykesville, United States
HQ citystring
Sykesville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
glycoengineered biologics, CHO cell engineering, ICAM-1 targeted delivery, lysosomal storage disorders, biopharmaceutical pipeline development
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Research and Development
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1geCHO BioDesign Platform
Description

Comprehensive panel of glycoengineered CHO cells capable of uniformly producing diverse human-like glycoforms of therapeutic proteins and vaccine antigens, combined with AI platforms for optimal glycoform identification and bioproduction optimization.

neuimmune.com
+1 more record
Core offering1 text field

NeuImmune develops a glycoengineering and targeted-delivery platform for producing precision biologics, including the geCHO BioDesign Platform and ICAM-1 Targeting Technology. It also advances preclinical therapeutic programs, including ICAM-1-ASM for Niemann-Pick disease and recombinant antithrombin for antithrombin deficiency.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • ICAM-1 targeting reduced brain storage of sphingomyelin substrate and secondary cholesterol in ASM knockout mice in preclinical studies
+1 more record
Product overview1 text field

NeuImmune is an early-stage biotechnology company offering a precision glycoengineering platform for biologics development. The core offering consists of the geCHO BioDesign Platform (glycoengineered CHO cell lines for producing human-like glycoforms) combined with ICAM-1 Targeting Technology (enhanced drug delivery via ICAM-1 receptor targeting). The company applies these platforms to develop pipeline candidates including ICAM-1-ASM for Niemann Pick Disease and recombinant Antithrombin for antithrombin deficiency, both enzyme replacement therapies for lysosomal storage disorders and rare diseases. NeuImmune operates as a platform-plus-pipeline model, licensing its technology while advancing proprietary therapeutic programs.

Product and service4 records
1geCHO BioDesign Platform
CategoryGlycoengineering Technology Platform
Description

A comprehensive panel of glycoengineered Chinese Hamster Ovary cells that uniformly produces diverse human-like glycoforms of therapeutic proteins and vaccine antigens, combined with AI platforms to identify optimal glycoforms for functional activity and bioproduction optimization.

2ICAM-1 Targeting Technology
CategoryTargeted Drug Delivery Technology
Description

A targeting technology that combines geCHO proteins with ICAM-1-binding peptides to enhance cellular delivery and enzymatic activity, enabling central nervous system and visceral-organ access through intravenous dosing for lysosomal storage disorders.

3ICAM-1-ASM (Niemann Pick Disease)
CategoryPreclinical Therapeutic Program
Description

A preclinical program targeting acid sphingomyelinase for Niemann-Pick disease types A and A/B. It uses an ICAM-1-ASM fusion protein to enable central nervous system delivery across the blood-brain barrier and address neurological involvement not covered by existing enzyme replacement therapy.

4Recombinant Antithrombin (rhAT)
CategoryPreclinical Therapeutic Program
Description

A preclinical program developing fully humanized recombinant antithrombin using the geCHO platform as an alternative to plasma-derived therapy, which carries blood-borne pathogen-transmission risks and has a short half-life.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Strategic collaboration to develop innovations strengthening domestic biomanufacturing of monoclonal antibodies targeting filoviruses such as Ebola and Sudan Viruses. NeuImmune contributes its geCHO BioDesign platform while Ginkgo provides cell-programming foundry, automation, and AI infrastructure. Project funded through BARDA's BioMaP-Consortium.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Avidity Biosciences
TypeEmerging player
Description

Avidity uses antibody-based targeted delivery to enable oligonucleotide therapeutics for serious genetic diseases. The company is comparable as an emerging antibody-delivery platform focused on rare disease, though its chemistry and target tissues differ from NeuImmune's protein therapeutics.

TypeOthers
Description

Ginkgo provides cell programming, automation, AI, and biomanufacturing infrastructure rather than competing therapeutic products. It is comparable to NeuImmune as a biological engineering and manufacturing platform, and it is also a named strategic collaborator.

TypeEmerging player
Description

Passage Bio develops genetic medicines for rare monogenic CNS disorders, with an emphasis on neurological disease and delivery to the brain. It is comparable in target indications and CNS focus, although Passage Bio uses gene therapy rather than glycoengineered proteins.

TypeBroad incumbent
Description

BioMarin is an established rare-disease biopharmaceutical company with commercial experience in enzyme-replacement and other specialty biologics, including lysosomal disorders. It provides a relevant commercial and development benchmark for NeuImmune's orphan-disease pipeline.

TypeDirect peer
Description

JCR Pharmaceuticals develops recombinant biopharmaceuticals for rare diseases and has a proprietary J-Brain Cargo technology for delivering biologics across the blood-brain barrier. Its combination of biologics manufacturing and targeted CNS delivery is closely comparable to NeuImmune's geCHO and ICAM-1 platforms.

TypeEmerging player
Description

Denali develops precision medicines for neurodegenerative and rare diseases and invests in blood-brain barrier shuttle technology for antibodies and enzyme-replacement programs. It is relevant as a biologics-delivery peer focused on improving CNS exposure, although its delivery modality differs from ICAM-1 targeting.

TypeDirect peer
Description

Selexis provides CHO cell-line development and recombinant-protein manufacturing technologies for biologics producers. Its cell-engineering platform is directly comparable to NeuImmune's use of glycoengineered CHO cells to optimize biologic production.

TypeDirect peer
Description

Glycotope develops human cell-line and glycoengineering platforms for producing optimized therapeutic antibodies and other glycoproteins. Its glycoengineering capabilities and platform-based business model make it a close technology peer to NeuImmune's geCHO system.

TypeEmerging player
Description

Sangamo develops engineered cell and gene therapies with programs in rare genetic diseases. It is a relevant platform-biotech comparator because it combines advanced biological engineering with specialty therapeutic development, although it does not share NeuImmune's glycoengineering focus.

TypeEmerging player
Description

Alcyone Therapeutics develops precision genetic medicines and CNS-delivery technologies for neurological and other rare diseases. Its platform-plus-pipeline approach and focus on controlled brain delivery are comparable to NeuImmune's ICAM-1 targeting strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuImmune

Biopharmaceutical Research and Developmentneuimmune.com

NeuImmune is an early-stage biotechnology company developing precision glycoengineered biologics using its proprietary geCHO BioDesign platform and ICAM-1 targeting technology, advancing preclinical pipeline programs for orphan diseases including Niemann-Pick disease and antithrombin deficiency.

What NeuImmune does

NeuImmune, Inc. is an early-stage biotechnology company developing precision glycoengineered biologics for orphan diseases and infectious disease applications. The company was founded in 2020 by scientists from the University of Maryland, University of California San Diego, and the Technical University of Denmark, and is headquartered in Sykesville, Maryland with 11-50 employees. Its core technology consists of two proprietary platforms: the geCHO BioDesign Platform, a comprehensive panel of glycoengineered Chinese Hamster Ovary (CHO) cells capable of uniformly producing diverse human-like glycoforms of therapeutic proteins and vaccine antigens, combined with AI tools for optimal glycoform identification and bioproduction optimization; and ICAM-1 Targeting Technology, which fuses geCHO proteins with ICAM-1-binding peptides to enable enhanced cellular delivery and enzymatic activity, including CNS and visceral organ access via intravenous dosing for lysosomal storage disorders. The company licenses the geCHO platform from a program developed with over $50M in support from the Novo Nordisk Foundation at the Technical University of Denmark.

NeuImmune operates a platform-plus-pipeline business model, applying its dual technology stack to advance preclinical pipeline programs including ICAM-1-ASM for Niemann-Pick Disease Types A and A/B (addressing neurological involvement not covered by existing enzyme replacement therapy Olipudase alfa) and recombinant Antithrombin (rhAT) for antithrombin deficiency. The company is pre-commercial with no disclosed product revenue; it monetizes through research grants, strategic government contracts (notably a $22.2M BARDA BioMaP-Consortium award for filovirus antibody biomanufacturing in partnership with Ginkgo Bioworks, announced November 2025), and a strategic licensing/government-funded collaboration model. Its customer segments are vertical-organized: primary focus on orphan disease patients with lysosomal storage disorders (particularly Niemann-Pick disease), and a secondary infectious disease segment targeting filoviral hemorrhagic fevers including Ebola and Sudan Virus. Pricing is not publicly disclosed as the company remains in preclinical development.

The company is led by Executive Chairman Thomas Fuerst, PhD (former Scientific Founder at MedImmune, Director of Biodefense at BARDA, and Director at DARPA), CTO Nathan Lewis, PhD (CHO genome sequencing pioneer and systems biology/AI expert), VP of gCHO Cell Manufacturing Bjorn Voldborg, MSc (former head of the NNF-funded National Biologics Facility at DTU), and Board Advisor Armand Girard, MBA (former CBO at GlycoMimetics and VP at Shire Pharmaceuticals). NeuImmune relies on scientific publications, press releases, and institutional partnerships (NIH, BARDA, Novo Nordisk Foundation, Ginkgo Bioworks, Kemp Proteins) for visibility and demand generation rather than commercial sales infrastructure.

NeuImmune firmographics

Firmographics
Name
NeuImmune
Legal name
NeuImmune, Inc.
Website
https://neuimmune.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuImmune is an early-stage biotechnology company developing precision glycoengineered biologics using its proprietary geCHO BioDesign platform and ICAM-1 targeting technology, advancing preclinical pipeline programs for orphan diseases including Niemann-Pick disease and antithrombin deficiency.
Ownership category
akta.pro rank

NeuImmune industry classification

Industry
Product category
Biopharmaceutical Research and Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Glycoengineered biologics
  • CHO cell engineering
  • ICAM-1 targeted delivery
  • Lysosomal storage disorders
  • Biopharmaceutical pipeline development

Where NeuImmune is headquartered

Location

Headquarters

HQ city
Sykesville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuImmune business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Distribution channels1 record

Marketing channels3 records

NeuImmune product offering

Product offering

Core offering

NeuImmune develops a glycoengineering and targeted-delivery platform for producing precision biologics, including the geCHO BioDesign Platform and ICAM-1 Targeting Technology. It also advances preclinical therapeutic programs, including ICAM-1-ASM for Niemann-Pick disease and recombinant antithrombin for antithrombin deficiency.

Product overview

NeuImmune is an early-stage biotechnology company offering a precision glycoengineering platform for biologics development. The core offering consists of the geCHO BioDesign Platform (glycoengineered CHO cell lines for producing human-like glycoforms) combined with ICAM-1 Targeting Technology (enhanced drug delivery via ICAM-1 receptor targeting). The company applies these platforms to develop pipeline candidates including ICAM-1-ASM for Niemann Pick Disease and recombinant Antithrombin for antithrombin deficiency, both enzyme replacement therapies for lysosomal storage disorders and rare diseases. NeuImmune operates as a platform-plus-pipeline model, licensing its technology while advancing proprietary therapeutic programs.

Differentiator

Problem solved

Functional benefit

Brands

  • geCHO BioDesign Platform: Comprehensive panel of glycoengineered CHO cells capable of uniformly producing diverse human-like glycoforms of therapeutic proteins and vaccine antigens, combined with AI platforms for optimal glycoform identification and bioproduction optimization.
  • ICAM-1 Targeting Technology

Products and services

  • geCHO BioDesign Platform A comprehensive panel of glycoengineered Chinese Hamster Ovary cells that uniformly produces diverse human-like glycoforms of therapeutic proteins and vaccine antigens, combined with AI platforms to identify optimal glycoforms for functional activity and bioproduction optimization.
  • ICAM-1 Targeting Technology A targeting technology that combines geCHO proteins with ICAM-1-binding peptides to enhance cellular delivery and enzymatic activity, enabling central nervous system and visceral-organ access through intravenous dosing for lysosomal storage disorders.
  • ICAM-1-ASM (Niemann Pick Disease) A preclinical program targeting acid sphingomyelinase for Niemann-Pick disease types A and A/B. It uses an ICAM-1-ASM fusion protein to enable central nervous system delivery across the blood-brain barrier and address neurological involvement not covered by existing enzyme replacement therapy.
  • Recombinant Antithrombin (rhAT) A preclinical program developing fully humanized recombinant antithrombin using the geCHO platform as an alternative to plasma-derived therapy, which carries blood-borne pathogen-transmission risks and has a short half-life.

Quantifiable outcome

  • ICAM-1 targeting reduced brain storage of sphingomyelin substrate and secondary cholesterol in ASM knockout mice in preclinical studies
  • +1 more outcomes

Companies that use NeuImmune

Customer profile

Segments2 records

Ideal customer profiles2 records

NeuImmune technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

NeuImmune partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ginkgo BioworkscoreStrategic or Co-development Partner · 4 November 2025Strategic collaboration to develop innovations strengthening domestic biomanufacturing of monoclonal antibodies targeting filoviruses such as Ebola and Sudan Viruses. NeuImmune contributes its geCHO BioDesign platform while Ginkgo provides cell-programming foundry, automation, and AI infrastructure. Project funded through BARDA's BioMaP-Consortium.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

NeuImmune competitors and assessment

Company assessment

Emerging players

  • Avidity Biosciences: Avidity uses antibody-based targeted delivery to enable oligonucleotide therapeutics for serious genetic diseases. The company is comparable as an emerging antibody-delivery platform focused on rare disease, though its chemistry and target tissues differ from NeuImmune's protein therapeutics.
  • Passage Bio: Passage Bio develops genetic medicines for rare monogenic CNS disorders, with an emphasis on neurological disease and delivery to the brain. It is comparable in target indications and CNS focus, although Passage Bio uses gene therapy rather than glycoengineered proteins.
  • Denali Therapeutics: Denali develops precision medicines for neurodegenerative and rare diseases and invests in blood-brain barrier shuttle technology for antibodies and enzyme-replacement programs. It is relevant as a biologics-delivery peer focused on improving CNS exposure, although its delivery modality differs from ICAM-1 targeting.
  • Sangamo Therapeutics: Sangamo develops engineered cell and gene therapies with programs in rare genetic diseases. It is a relevant platform-biotech comparator because it combines advanced biological engineering with specialty therapeutic development, although it does not share NeuImmune's glycoengineering focus.
  • Alcyone Therapeutics: Alcyone Therapeutics develops precision genetic medicines and CNS-delivery technologies for neurological and other rare diseases. Its platform-plus-pipeline approach and focus on controlled brain delivery are comparable to NeuImmune's ICAM-1 targeting strategy.

Others

  • Ginkgo Bioworks: Ginkgo provides cell programming, automation, AI, and biomanufacturing infrastructure rather than competing therapeutic products. It is comparable to NeuImmune as a biological engineering and manufacturing platform, and it is also a named strategic collaborator.

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is an established rare-disease biopharmaceutical company with commercial experience in enzyme-replacement and other specialty biologics, including lysosomal disorders. It provides a relevant commercial and development benchmark for NeuImmune's orphan-disease pipeline.

Direct peers

  • JCR Pharmaceuticals: JCR Pharmaceuticals develops recombinant biopharmaceuticals for rare diseases and has a proprietary J-Brain Cargo technology for delivering biologics across the blood-brain barrier. Its combination of biologics manufacturing and targeted CNS delivery is closely comparable to NeuImmune's geCHO and ICAM-1 platforms.
  • Selexis: Selexis provides CHO cell-line development and recombinant-protein manufacturing technologies for biologics producers. Its cell-engineering platform is directly comparable to NeuImmune's use of glycoengineered CHO cells to optimize biologic production.
  • Glycotope: Glycotope develops human cell-line and glycoengineering platforms for producing optimized therapeutic antibodies and other glycoproteins. Its glycoengineering capabilities and platform-based business model make it a close technology peer to NeuImmune's geCHO system.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

NeuImmune social profiles

Digital presence

NeuImmune financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuImmune leadership team

Management profile

Number of profiles

Profiles4 records

NeuImmune funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuImmune M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuImmune

What does NeuImmune do?

NeuImmune develops a glycoengineering and targeted-delivery platform for producing precision biologics, including the geCHO BioDesign Platform and ICAM-1 Targeting Technology. It also advances preclinical therapeutic programs, including ICAM-1-ASM for Niemann-Pick disease and recombinant antithrombin for antithrombin deficiency.

Is NeuImmune a public or private company?

NeuImmune is a private company. It is classified as unknown and is currently operating.

When was NeuImmune founded?

NeuImmune was founded in 2020. It employs 11 to 50 people.

Where is NeuImmune based?

NeuImmune is headquartered in Sykesville, United States, in the North America region.

Who are NeuImmune's main competitors?

Emerging players on record are Avidity Biosciences, Passage Bio, Denali Therapeutics, Sangamo Therapeutics and Alcyone Therapeutics. Ginkgo Bioworks is listed as an others. BioMarin Pharmaceutical is listed as a broad incumbent. Direct peers are JCR Pharmaceuticals, Selexis and Glycotope.

Does NeuImmune have an API?

No public API is recorded for NeuImmune.

What industry is NeuImmune in?

NeuImmune's product category is Biopharmaceutical Research and Development. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals